Molecule guides
BPC-157 + TB-500 (Wolverine Blend): Composition, Molar Arithmetic and Certificate Checks
Two unrelated repair-model peptides in one vial: what each contributes, the molar mismatch a 1:1 mass ratio hides, and how a blend certificate must be written.
The Wolverine blend, catalogued as BPC-157 + TB-500, is one lyophilized vial holding two structurally unrelated repair-model peptides co-lyophilized at equal mass: BPC-157, the 15-residue gastric pentadecapeptide, and TB-500, the 7-residue acetylated actin-binding fragment of thymosin beta-4. A 10 mg vial holds 5 mg of each and a 20 mg vial 10 mg of each. The product exists because several published repair protocols use both sequences at once, and a single vial eliminates one reconstitution, one stopper puncture and one opportunity for pipetting error.
It also creates a complication no single-peptide vial has: equal mass does not mean equal moles. This page explains what the two components are, how their mechanisms differ, why the ratio arithmetic deserves attention, and how a certificate for a two-component product should read. The Wolverine blend is supplied for laboratory research only.
The two peptides and why they are paired
BPC-157 is a 15-residue piece of a protein first isolated from human gastric juice, occasionally referred to as body protection compound. Nothing else in the catalogue closely resembles it structurally, and its literature is dominated by rodent gastrointestinal, tendon and vascular models, with reported influences on new vessel formation, growth-factor receptor expression and nitric oxide signalling.
TB-500 is something else altogether: seven residues, acetylated at the N-terminus, matching the actin-binding motif of thymosin beta-4, the 43-residue protein that serves as the main G-actin sequestering molecule in mammalian cells. Its literature concerns cytoskeletal dynamics, cell migration and repair models in cornea and heart. It is a fragment and not the entire protein, a distinction that matters, since the full 43-residue protein is a separate product with its own literature.
Convention, not biology, groups these two together. They share the type of model they appear in, not a pathway. That is exactly the reason researchers pair them: the published repair literature argues that vascular and growth-factor endpoints on the one hand, and cell-migration and cytoskeletal endpoints on the other, cover different aspects of a single process. Whether combining them achieves anything beyond either component alone remains unresolved in published work, so any experiment framed around that question needs single-peptide arms in the design.
Why the ratio arithmetic matters
The blend is equal by mass. Since BPC-157 has a mass of 1419.55 g/mol and TB-500 of 889.02 g/mol, equal masses do not give equal molar amounts. A 10 mg vial holds 5 mg of BPC-157, roughly 3.52 micromoles, alongside 5 mg of TB-500, roughly 5.62 micromoles, so there is about 60% more TB-500 in molar terms. If the readout is in mass units this makes no difference; for receptor-level or molar-equivalence comparisons it is a real discrepancy that belongs in the methods section rather than being quietly ignored.
This applies to blends in general rather than being a flaw in this one, and it is among the main reasons researchers sometimes choose separate vials. Our guide to peptide blends versus single vials examines the trade-off in full.
Proposed mechanisms of each component
BPC-157
Published mechanisms include increased signalling through vascular endothelial growth factor receptor 2 with associated angiogenic responses, interaction with the nitric oxide system and changes in growth-factor expression in damaged tissue. Rodent studies report faster closure and better tensile properties in tendon and gastrointestinal injury models. No receptor has been established for the peptide, and much of the mechanistic story is inferred from pathway readouts rather than from binding data.
TB-500
Those seven residues carry thymosin beta-4's actin-binding motif. Sequestering G-actin changes the monomer pool available for filament assembly, which affects cell motility, and that is the mechanism most commonly invoked for migration and repair findings. Whether a short fragment behaves like the intact 43-residue protein is an open question, explored in our article on why a fragment is not the entire protein.
Everything here is preclinical. Neither peptide has an approved use, and neither has a meaningful controlled human trial record.
Formats and sizes
We stock the Wolverine blend as lyophilized vials of 10 mg (5 mg of each component, €130) and 20 mg (10 mg of each, €230). Each peptide is synthesised and purified separately to at least 99% before the two are combined and co-lyophilized, so the certificate characterises each peptide individually rather than treating the mixture as one substance.
Comparable preparations include the four-component KLOW blend and the three-component GLOW blend, all grouped under recovery blends. Single vials of each component are still available for designs that require independent control over the two concentrations.
Reconstitution and storage in the lab
Reconstituting a blend means running the single-peptide calculation twice. Add 2 mL of bacteriostatic water to a 10 mg vial and you get 5 mg/mL of total peptide, that is 2.5 mg/mL of BPC-157 and 2.5 mg/mL of TB-500. Withdrawing 0.1 mL (10 units on a U-100 syringe) takes out 500 mcg in total, 250 mcg of each. Molar terms put roughly 176 nanomoles of BPC-157 and roughly 281 nanomoles of TB-500 in that same 0.1 mL. Recording both numbers instead of the total mass alone is what makes a blend experiment reproducible.
Both peptides dissolve easily in aqueous diluent. Add it slowly against the vial wall, swirl rather than shake, and check that dissolution is complete and the solution clear. Store lyophilized vials at −20 °C, shielded from light and moisture; refrigerate reconstituted solution and split it into aliquots so one container is not warmed and cooled over and over. Methods are set out in the reconstitution guide and the storage guide.
Reading a certificate for a blend
A product with two components demands a certificate built accordingly, and this is where blends are most often misrepresented commercially. Our certificate for this blend covers BPC-157 and TB-500 individually, each with its own purity value, chromatogram and mass confirmation, tied to the vial lot number. Three checks follow.
Make sure you are looking at two data sets rather than one. A lone purity figure for a mixture is not meaningful, because a blend's chromatogram legitimately displays two large peaks, and a naive purity calculation on such a trace would come out near 50%. Verify both masses next: 1419.55 g/mol for BPC-157 and 889.02 g/mol for TB-500, with the acetyl group included. Finally, check that the stated ratio is a specification carrying a tolerance rather than an assumption, since the ratio is fixed at blending and is the one property a downstream buyer cannot confirm by inspection. Our COA reading guide explains the underlying analytical methods.
Regulatory position
Neither component is an authorised medicine in the EU, the United States or elsewhere, and the blend is neither a food supplement nor a generally available compounded preparation. BPC-157 especially has attracted regulatory scrutiny in the compounding context in recent years.
Related compounds and further reading
For a mechanistic contrast between the two components, read BPC-157 vs TB-500. For how multi-peptide recovery preparations are put together and where their ratios originate, see our article on how recovery blends are composed.
Questions
What does the Wolverine blend contain?
Two peptides co-lyophilized at equal mass in one vial: BPC-157, a 15-residue fragment of a gastric juice protein with a mass of 1419.55 g/mol, and TB-500, the seven-residue N-acetylated actin-binding fragment of thymosin beta-4 at 889.02 g/mol. The 10 mg vial holds 5 mg of each and the 20 mg vial 10 mg of each.
Does a 1:1 blend hold the same quantity of both peptides?
By weight yes, by moles no. In a 10 mg vial, 5 mg of BPC-157 equals roughly 3.52 micromoles while 5 mg of TB-500 equals roughly 5.62 micromoles, about 60% more. Mass-based readouts are unaffected, but molar-equivalence work needs this difference recorded in the method.
What is the rationale for combining them?
Published repair work suggests each addresses a different aspect of the same process: BPC-157 through angiogenic and growth-factor signalling, TB-500 through actin dynamics and cell migration. Whether the pair achieves more than either alone remains unsettled, so studies asking that question require single-peptide comparison arms.
Are the two peptides related?
Not at all. They derive from different parent proteins, differ in length, share no sequence homology and have no pathway in common. What links them is the type of injury model in which they appear, not their biology, and treating them as variants of one another is a frequent misreading of this part of the catalogue.
How should the certificate for a blend be read?
Each component must be reported on its own, with its own purity figure, chromatogram and mass confirmation matched to the vial lot. One purity number for the mixture means nothing, since a blend chromatogram properly shows two large peaks. Check 1419.55 g/mol for BPC-157 and 889.02 g/mol for acetylated TB-500, and confirm the ratio is a specification with a tolerance.
What is the reconstitution calculation?
The single-peptide calculation performed twice. Adding 2 mL of bacteriostatic water to a 10 mg vial yields 5 mg/mL total, meaning 2.5 mg/mL of each. Drawing 0.1 mL, the 10-unit mark on a U-100 syringe, gives 500 mcg in total or 250 mcg of each, equivalent to about 176 nanomoles of BPC-157 and 281 nanomoles of TB-500.
Does TB-500 equal thymosin beta-4?
No. TB-500 is a seven-residue fragment bearing the actin-binding motif of thymosin beta-4, itself a 43-residue protein. Whether the fragment reproduces the intact protein's behaviour is still debated in the literature, and full-length thymosin beta-4 is stocked separately for research needing the whole molecule.
Is the Wolverine blend approved or otherwise authorised?
Neither component is an approved medicine anywhere, and the blend is neither a food supplement nor a generally available compounded preparation. BPC-157 in particular has attracted regulatory scrutiny in the compounding context.